Nexstim

Nexstim continued its multi-year growth streak in H2 and guided for continued growth this year.

We expect full-year EBIT to turn clearly profitable.

The use of the NBS 6 system is expanding to post-brain surgery rehabilitation.

The marketing authorization for the NBS 6 system in the United Arab Emirates opens up a new market and supports our estimates for future growth.

In Nexstim's system sales, the summer of 2025 was particularly busy and helped the company achieve a full-year sales record in terms of units.

The agreement ensures continued cooperation until 2026, but the payment arrangement has shifted from an original cash-based plan to one weighted toward convertible debt.